Rheumatoid Arthritis | Chart Trends | US | 2014

The Rheumatoid Arthritis (RA) treatment paradigm continues to evolve as new therapeutic options are added to physicians’ toolkits. The positioning of newer agents (e.g., Pfizer’s Xeljanz, Janssen’s Simponi Aria) in the treatment algorithm is still being established in some cases, and has reached a relative steady state in others. ChartTrends®: Rheumatoid Arthritis (US) 2014 explores the current status quo in RA treatment based on both physician reports and actual practice through the use of patient chart data.

Login to access report

launch Related Market Assessment Reports